Candid's Strategy with $370M Investment in Bispecifics for Autoimmune Diseases

Monday, 9 September 2024, 02:00

Candid is investing $370M to prove bispecifics' efficacy in autoimmune diseases. The startup believes T cell engagers will outperform traditional therapies in targeting inflammatory conditions.
LivaRava_Medicine_Default.png
Candid's Strategy with $370M Investment in Bispecifics for Autoimmune Diseases

Candid's Ambitious Venture into Bispecifics

Candid, with a substantial investment of $370 million, is on a mission to validate the potential of bispecifics in treating autoimmune diseases. According to the CEO, the focus is on T cell engagers as the optimal choice in developing new treatments for inflammatory diseases. This strategy positions Candid as a pivotal player in the evolving landscape of autoimmune therapies.

Why T Cell Engagers?

The startup contends that T cell engagers might be more effective than traditional cell therapies due to their unique mechanism of action. By targeting the immune system more precisely, these treatments promise to enhance patient outcomes in various inflammatory conditions.

  • Investment in Research and Development
  • Potential for Groundbreaking Treatments
  • Focus on Inflammatory Disease Areas

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe